{"id":"https://genegraph.clinicalgenome.org/r/ddadc3c7-7971-4644-b1ec-992b0a491fe7v2.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between PEX1 and peroxisome biogenesis disorder (types 1A and 1B and Heimler syndrome included), an autosomal recessive disorder, was evaluated using the ClinGen Clinical Validity Framework as of May 17, 2019. PEX1 encodes a cytosolic AAA protein (ATPase associated with diverse cellular activities) involved in peroxisomal matrix protein import. Peroxisomal biogenesis disorders are caused by defects in various stages of peroxisomal protein import and/or peroxisome biogenesis. There are at least 14 PEX genes implicated in peroxisome biogenesis disorders, with PEX1 being the most commonly affected gene in patients with a frequency of ~60% (Waterham and Ebberink 2012, PMID 22871920). Variants in PEX1 were first reported in humans with peroxisomal biogenesis disorder in 1997 (Reuber et al., PMID 9398847). Data from 9 patients with 10 unique variants (missense, nonsense, frameshift, splicing) from 4 publications were curated (Reuber et al., 1997, PMID 9398847; Walter et al., 2001, PMID 11389485; Sun et al., 2013, PMID 23247051; Ratbi et al., 2015, PMID 26387595). Additional cases are available in the literature but the maximum score for genetic evidence (12 points) has been reached. The relationship between PEX1 and peroxisome biogenesis disorder is supported by experimental evidence including a biochemical function similar to other PEX genes implicated in peroxisome biogenesis disorders (Waterham et al., 2012, PMID 22871920), in vitro assays (Reuber et al., 1997, PMID 9398847; Walter et al., 2001, PMID 11389485), a protein interaction with PEX6 (Matsumoto et al., 2003, PMID 12717447), which is encoded by a known peroxisome biogenesis disorder gene, and a mouse model (Heibler et al., 2014, PMID 24503136).  In summary, PEX1 is definitively associated with peroxisome biogenesis disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. The classification was approved by the ClinGen Peroxisomal Disorders Gene Curation Expert Panel on May 17, 2019.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/ddadc3c7-7971-4644-b1ec-992b0a491fe7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:sopChange"},{"id":"cg:otherTextChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10049","date":"2023-09-06T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10049","date":"2023-09-06T13:31:08.951Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dfa09031-9932-4fa4-8ab7-d944842e4736_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dfa09031-9932-4fa4-8ab7-d944842e4736","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23247051","rdfs:label":"Sun 2013 Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/0aca35da-6e5c-45a0-b5ef-0056302aa7ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.475G>C (p.Ala159Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368201880"}},{"id":"https://genegraph.clinicalgenome.org/r/b3b9d569-b534-45f5-9a2c-8ae219e0f9d9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.782_783del (p.Gln261ArgfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/188910"}}],"detectionMethod":"NGS in family: coding exons of the 13 PEX genes and flanking intron regions). Sanger sequencing to confirm.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0001251","obo:HP_0005280","obo:HP_0000365","obo:HP_0001263","obo:HP_0002240","obo:HP_0000218","obo:HP_0008947","obo:HP_0001410","obo:HP_0006579","obo:HP_0000639"],"previousTesting":true,"previousTestingDescription":"C22:0 4.42 uM (ref 26-82); C24:0 11.26 uM (ref 19-55); C24:1 12.26 uM (ref 25-120); C26:0 4.13 (ref 0.3-0.7); C24:0/C22:0 2.55 (ref <0.94); C26:0/C22:0 0.934 (ref <0.018).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ec0da246-d96b-41ac-a661-f61f6b7d13f0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23247051","allele":{"id":"https://genegraph.clinicalgenome.org/r/b3b9d569-b534-45f5-9a2c-8ae219e0f9d9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/b1804d0e-2097-4d43-bbac-e3d648f93827_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23247051","allele":{"id":"https://genegraph.clinicalgenome.org/r/0aca35da-6e5c-45a0-b5ef-0056302aa7ed"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/ec0da246-d96b-41ac-a661-f61f6b7d13f0","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec0da246-d96b-41ac-a661-f61f6b7d13f0_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b1804d0e-2097-4d43-bbac-e3d648f93827","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b1804d0e-2097-4d43-bbac-e3d648f93827_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/31432d65-e527-4c80-8d48-b101b5ef1caa_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31432d65-e527-4c80-8d48-b101b5ef1caa","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","rdfs:label":"II:1, Family 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9e216623-157c-4091-8186-9d0291461ccb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.1239+1G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/217430"}},"detectionMethod":"WES followed by Sanger sequencing to confirm. Sanger sequencing on additional family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Normal intellect.","phenotypes":["obo:HP_0000705","obo:HP_0008619"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9f29e85e-105b-4514-aa1c-22dd88dfffe6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","allele":{"id":"https://genegraph.clinicalgenome.org/r/9e216623-157c-4091-8186-9d0291461ccb"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}},{"id":"https://genegraph.clinicalgenome.org/r/9f29e85e-105b-4514-aa1c-22dd88dfffe6","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9f29e85e-105b-4514-aa1c-22dd88dfffe6_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e12232f8-4a52-45ba-a4ab-4ee226fee6a8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e12232f8-4a52-45ba-a4ab-4ee226fee6a8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","rdfs:label":"Case 27","ageType":"AgeAtReport","ageUnit":"Years","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1d060b77-f3bc-4bf7-a66f-1b2973a50a2b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.2528G>A (p.Gly843Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7516"}},"detectionMethod":"All 24 PEX1 exons amplified from fibroblasts DNA with use of intronic primer pairs and analyzed by SSCP. Fragments with unusual patterns were sequenced directly.","firstTestingMethod":"SSCP","phenotypeFreeText":"Phenotypes not specified, part of \"nonclassical ZS\" group that has less pronounced abnormalities and longer survival than classical ZS group.","previousTesting":true,"previousTestingDescription":"PEX1 protein level: 10% of control; VLCFA C26:C22 ratio 0.12 (control 0.03-0.07); DHAPAT activity (mnol/2h x mg protein) 2.4 (control 8.5 +/- 2.0).","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f0148e2c-09ef-4c9e-ae40-5522ce7ed588_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","allele":{"id":"https://genegraph.clinicalgenome.org/r/1d060b77-f3bc-4bf7-a66f-1b2973a50a2b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f0148e2c-09ef-4c9e-ae40-5522ce7ed588","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0148e2c-09ef-4c9e-ae40-5522ce7ed588_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f0148e2c-09ef-4c9e-ae40-5522ce7ed588_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"his is the most common variant in ZS. Functional studies in a patient-derived cell line suggest that the G843D variant has reduced ability to import proteins as compared to wild type (Reuber et al., 1997).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7652a318-e49a-41b7-9391-ece687fc4f14_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7652a318-e49a-41b7-9391-ece687fc4f14","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","rdfs:label":"Case 11","ageType":"AgeAtReport","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e1b3b0a4-6580-447b-9c00-4f6d149921ad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.2730del (p.Leu910PhefsTer51)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/188971"}},"detectionMethod":"All 24 PEX1 exons amplified from fibroblasts DNA with use of intronic primer pairs and analyzed by SSCP. Fragments with unusual patterns were sequenced directly.","firstTestingMethod":"SSCP","phenotypeFreeText":"Phenotypes not specified, part of \"classical ZS\" group (craniofacial dysrmorphia, severe neurological abnormalities, hypotonia, eye abnormalities, early death).","previousTesting":true,"previousTestingDescription":"PEX1 protein level: 0% of control; VLCFA C26:C22 ratio 0.31 (control 0.03-0.07); DHAPAT activity (mnol/2h x mg protein) 0.1 (control 8.5 +/- 2.0).","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/765f47c8-0480-4b56-9fe2-205e6cd693c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","allele":{"id":"https://genegraph.clinicalgenome.org/r/e1b3b0a4-6580-447b-9c00-4f6d149921ad"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/765f47c8-0480-4b56-9fe2-205e6cd693c1","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/765f47c8-0480-4b56-9fe2-205e6cd693c1_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/7ea4b933-5467-404a-be77-d324668f77cb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ea4b933-5467-404a-be77-d324668f77cb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","rdfs:label":"Case 17","ageType":"AgeAtReport","ageUnit":"Months","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4df1d6c4-22e5-4197-b4e3-e7af60f29681","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.2097dup (p.Ile700TyrfsTer42)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7519"}},"detectionMethod":"All 24 PEX1 exons amplified from fibroblasts DNA with use of intronic primer pairs and analyzed by SSCP. Fragments with unusual patterns were sequenced directly.","firstTestingMethod":"SSCP","phenotypeFreeText":"Phenotypes not specified, part of \"classical ZS\" group (craniofacial dysrmorphia, severe neurological abnormalities, hypotonia, eye abnormalities, early death).","previousTesting":true,"previousTestingDescription":"PEX1 protein level: 0% of control; VLCFA C26:C22 ratio 0.52 (control 0.03-0.07); DHAPAT activity (mnol/2h x mg protein) 0.5 (control 8.5 +/- 2.0).","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e8f5476-8edf-4921-8d5d-05ebabb4a4ce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","allele":{"id":"https://genegraph.clinicalgenome.org/r/4df1d6c4-22e5-4197-b4e3-e7af60f29681"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/3e8f5476-8edf-4921-8d5d-05ebabb4a4ce","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e8f5476-8edf-4921-8d5d-05ebabb4a4ce_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/2c86b9b3-f96e-4ad9-b0e5-171b52909fb7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c86b9b3-f96e-4ad9-b0e5-171b52909fb7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9398847","rdfs:label":"PBD009","allele":{"id":"https://genegraph.clinicalgenome.org/r/cd96afb5-716c-487a-a7b9-817c7d94ee55","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.2926+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/188729"}},"detectionMethod":"PCR amplification of PEX1 cDNA by RT-PCR followed by sequencing. Confirmed in genomic DNA.","phenotypeFreeText":"Diagnosis of Zellweger syndrome. This patient comes from previous studies of using patient cells for complementation testing.","previousTesting":true,"previousTestingDescription":"Import of PTS1 and PTS1 proteins was assessed by innumofluorescence microscopy. There was no import of these proteins in fibroblasts. VLCFA oxidation as expressed as a ratio of C26:C22 FAO activity was 0.98. Plasmalogen synthesis as expressed as the ratio of the second half of the pathway (ER-based) to the total pathway (peroxisomal steps plus ER steps) was 4.65. The higher the ratio, the lower the activity of peroxisomal enzymes.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ce27da9f-d53e-40e7-b671-573a09baba79_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9398847","allele":{"id":"https://genegraph.clinicalgenome.org/r/cd96afb5-716c-487a-a7b9-817c7d94ee55"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/ce27da9f-d53e-40e7-b671-573a09baba79","type":"EvidenceLine","dc:description":"Northern blot analysis on patient cells showed no detectable PEX1 transcript.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce27da9f-d53e-40e7-b671-573a09baba79_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/63b68448-ba8e-429d-8410-b9104ff36454_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/63b68448-ba8e-429d-8410-b9104ff36454","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","rdfs:label":"II:3, Family 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3db4fe91-2631-42a0-9df0-673ec44aa16b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.3750G>A (p.Trp1250Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/217431"}},"detectionMethod":"WES followed by Sanger sequencing to confirm. WES also performed on 2 family members (I:1, II:1). Sanger sequencing on additional family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Normal intellect","phenotypes":["obo:HP_0008619","obo:HP_0000705"],"previousTesting":true,"previousTestingDescription":"Blood analysis- VLCFA: C22:0, C24:0, C26:0 normal; VLCFA ratio C24:0/C22:0, C26:0/C22:0 normal; bile acids: DHCA, THCA normal; phytanic acid, pristanic acid, pipecolic acid normal. In eurythrocytes, plasmalogens: C16:0 DMA, C18:0 DMA normal. In fibroblasts- VLCFA (umol/l): C22:0 4.43 (ZS range 2.36-5.59; control 3.84-10.2), C24:0 8.36 (ZS range 5.41-13.39; control 7.76-17.66), C26:0 0.24 (ZS range 0.59-3.38; control 0.18-0.38). VLCFA ratio: C24:0/C22:0 1.89 (ZS range 2.08-3.4; control 1.55-2.3); C26:0/C22:0 0.05 (ZS range 0.011-1.17; control 0.03-0.07). DHAPAT activity [(nmol/(2h.mg protein)] 7.1 (ZS range 0.1-0.9; control 5.4-10.6). Alpha oxidation activity [pmol/(hxmg protein)] = 34 (ZS range 0-10, control 28-95). Beta oxidation activity [pmol/(hxmg protein)]: C16:0 substrate 7,162 (ZS and control range 3,330-7,7900); C26:0 substrate 1,088 (ZS range 50-350; control 800-2,040); pristanic acid substrate 1,092 (ZS range 0-30; control 790-1,690).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/68d0b4d9-1473-439f-b9d9-cf26d0d102e4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","allele":{"id":"https://genegraph.clinicalgenome.org/r/3db4fe91-2631-42a0-9df0-673ec44aa16b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/68d0b4d9-1473-439f-b9d9-cf26d0d102e4","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/68d0b4d9-1473-439f-b9d9-cf26d0d102e4_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/05755180-6724-45b0-a5e5-e2f64273a73e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05755180-6724-45b0-a5e5-e2f64273a73e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","rdfs:label":"II:2, Family 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":29,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/2799d486-5bac-4474-8f8f-bd5ebce9f062","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.2114T>G (p.Leu705Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/217428"}},{"id":"https://genegraph.clinicalgenome.org/r/4df1d6c4-22e5-4197-b4e3-e7af60f29681"}],"detectionMethod":"WES followed by Sanger sequencing to confirm. Sanger sequencing on additional family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Normal intellect, Beau's lines","phenotypes":["obo:HP_0007703","obo:HP_0008619","obo:HP_0001820","obo:HP_0000705","obo:HP_0001597","obo:HP_0007754"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/df360c06-f91f-4cd9-b90e-64e803ccb2a8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","allele":{"id":"https://genegraph.clinicalgenome.org/r/2799d486-5bac-4474-8f8f-bd5ebce9f062"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/4f003aa1-c9b5-4396-9836-0ea372a7f093_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","allele":{"id":"https://genegraph.clinicalgenome.org/r/4df1d6c4-22e5-4197-b4e3-e7af60f29681"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/4f003aa1-c9b5-4396-9836-0ea372a7f093","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f003aa1-c9b5-4396-9836-0ea372a7f093_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/df360c06-f91f-4cd9-b90e-64e803ccb2a8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df360c06-f91f-4cd9-b90e-64e803ccb2a8_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/df360c06-f91f-4cd9-b90e-64e803ccb2a8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When transfected into PEX1 deficient cells rescued peroxisome biogenesis in ~60% of cells, suggesting that it is a very mild variant. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/4905fcb8-b95b-43d3-8cd2-72957843a6e0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4905fcb8-b95b-43d3-8cd2-72957843a6e0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","rdfs:label":"II:1, Family 4","ageType":"AgeAtReport","ageUnit":"Years","ageValue":24,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/4df1d6c4-22e5-4197-b4e3-e7af60f29681"},{"id":"https://genegraph.clinicalgenome.org/r/3335912e-df97-426b-abfa-d7807dd66113","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000466.3(PEX1):c.1742G>C (p.Arg581Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/217429"}}],"detectionMethod":"WES followed by Sanger sequencing to confirm. Sanger sequencing on additional family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Normal intellect.","phenotypes":["obo:HP_0008619","obo:HP_0000705","obo:HP_0007703"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/59612176-503a-4c20-a632-7a90589a764a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","allele":{"id":"https://genegraph.clinicalgenome.org/r/4df1d6c4-22e5-4197-b4e3-e7af60f29681"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/f86e33f0-f64f-4dbd-9e86-b64207420fe9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26387595","allele":{"id":"https://genegraph.clinicalgenome.org/r/3335912e-df97-426b-abfa-d7807dd66113"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/59612176-503a-4c20-a632-7a90589a764a","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59612176-503a-4c20-a632-7a90589a764a_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f86e33f0-f64f-4dbd-9e86-b64207420fe9","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f86e33f0-f64f-4dbd-9e86-b64207420fe9_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/974cbaed-fefe-4a53-9a15-b293140e855c","type":"EvidenceLine","dc:description":"Multiple proteins all associated with PBD.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9afdd7af-b45f-4269-950e-1a7d2fd3b02b","type":"Finding","dc:description":"Cystolic proteins PEX1 and PEX6 interact with one another, are anchored to the peroxisomal membrane via PEX26 and are involved in the release of ubiquitinated PEX5 from the peroxisomal membrane. PEX6, in addition to PEX5 and PEX26, have all been implicated in PBDs.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12717447","rdfs:label":"PEX1/PEX6 Protein Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1a474e4f-92d4-43f6-ba84-9c14e7954503","type":"EvidenceLine","dc:description":"Increased points since there are 12 PEX genes all involved in the same types of disorders.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f319b60d-e316-424a-9f81-6c5f97b164f8","type":"Finding","dc:description":"PBDs can be caused by a defect in any of at least 14 different PEX genes, which encode peroxins that are involved in various stages of peroxisomal protein import and/or biogenesis of peroxisomes. Complementation testing established which genes are involved in PBDs.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22871920","rdfs:label":"PEX Genes","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/334fc47e-e8e3-43d7-a7f6-e88eba49d321","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b88574ed-7bab-4faf-a045-3eda4effb09f","type":"FunctionalAlteration","dc:description":"Investigated whether phenotype severity correlates with peroxisomal function and amount of PEX1 protein. Patients were split into 2 categories: (1) classical ZS (craniofacial dysrmorphia, severe neurological abnormalities, hypotonia, eye abnormalities, early death) and (2) non classical ZS (mainly patients with NALD or IRD who show less pronounced abnormalities and longer survival). Patients with the G843D allele had resicudal protein 3-15% normal, had the milder phenotypes, and survival was >2 years (1 exception). Patients homozygous for P740X had no PEX1, severe phenotypes, and lower survival. There is also a slight tendency for a more severe biochemical phenotype for classical ZS (VLCAF C26:C22 ratio was 0.48+/-0.14 vs 0.31+/-0.16 for non classical ZS; DHAPAT activity was 0.58+/-0.55 nmol/2hxmg protein vs 1.59+/-1.07 for non classical ZS).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11389485","rdfs:label":"Patient Cells PEX1 Activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a345ba65-9dcd-43dd-a1c2-1778c1a921ea_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0ccc0d72-6818-4a17-8590-f22a8272294a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6cddf3ea-2604-4de2-8b8d-d5615cae66fc","type":"Finding","dc:description":"Newly synthesized peroxisomal proteins carry a persoxomal targeting signal (PTS1 or PTS2 for matrix enzymes). PEX1 is required for both PTS1 and PTS2 protein import. Expression of PEX1 restored peroxisomal (PTS1 and PTS2) protein import in cells from PBD009 who is homozygous for c.2926+1G>A. Vesicular staining (Figure 2) represents protein import from peroxisomes by co-localization.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9398847","rdfs:label":"Patient Cell Rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0a69ca1a-9a6e-4efc-aa0a-fb9d25bb2f47","type":"EvidenceLine","dc:description":"G843D is the most common hypomorphic variant reported in ZSD patients with milder phenotypes. This mouse recapitulated many of those phenotypes such as growth retardation and metabolic abnormalities.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb88a27c-3008-4250-a2a9-be34f18c047e","type":"Finding","dc:description":"Murine PEX-1-G844D knock in mice, which is the ortholog to human PEX1-G843D, were generated using gene targeting. Homozygous mice showed growth retardation, decreased liver function, increased C26:0, C26:1 and C26.2 fatty acids, impaired DHA synthesis, reduced PE plasmalogen levels in blood spots, DHCA and THCA (bile acid intermediates) were elevated in all tissues tested.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24503136","rdfs:label":"G844D KI Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":6811,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/lHYyoTxajI0","type":"GeneValidityProposition","disease":"obo:MONDO_0019234","gene":"hgnc:8850","modeOfInheritance":"obo:HP_0000007"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a345ba65-9dcd-43dd-a1c2-1778c1a921ea-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}